U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06912529) titled 'Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma' on March 24.
Brief Summary: This phase II study will evaluate the efficacy, safety and tolerability of second-line treatment with axicabtagene ciloleucel in primary mediastinal B-cell lymphoma patients (PMBCL).
Study Start Date: March 13
Study Type: INTERVENTIONAL
Condition:
B-cell Lymphoma Refractory
B-cell Lymphoma Recurrent
Intervention:
PROCEDURE: Leukapheresis
Axicabtagene ciloleucel is prepared from the patient's peripheral blood mononuclear cells, which are obtained via a standard leukapheresis procedure.
D...